FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316987218> ?p ?o ?g. }

• W2316987218 endingPage "3758" @default.
• W2316987218 startingPage "3758" @default.
• W2316987218 abstract "To investigate the biological effects of internal irradiation, and the therapeutic effectiveness was assessed of (131)I-labeled anti-epidermal growth factor receptor (EGFR) liposomes, derived from cetuximab, when used as a tumor-targeting carrier in a colorectal cancer mouse model.We described the liposomes and characterized their EGFR-targeted binding and cellular uptake in EGFR-overexpressing LS180 colorectal cancer cells. After intra-tumor injections of 74 MBq (740 MBq/mL) (131)I-antiEGFR-BSA-PCL, we investigated the biological effects of internal irradiation and the therapeutic efficacy of (131)I-antiEGFR-BSA-PCL on colorectal cancer in a male BALB/c mouse model. Tumor size, body weight, histopathology, and SPECT imaging were monitored for 33 d post-therapy.The rapid radioiodine uptake of (131)I-antiEGFR-BSA-PCL and (131)I-BSA-PCL reached maximum levels at 4 h after incubation, and the (131)I uptake of (131)I-antiEGFR-BSA-PCL was higher than that of (131)I-BSA-PCL in vitro. The (131)I tissue distribution assay revealed that (131)I-antiEGFR-BSA-PCL was markedly taken up by the tumor. Furthermore, a tissue distribution assay revealed that (131)I-antiEGFR-BSA-PCL was markedly taken up by the tumor and reached its maximal uptake value of 21.0 ± 1.01 %ID/g (%ID/g is the percentage injected dose per gram of tissue) at 72 h following therapy; the drug concentration in the tumor was higher than that in the liver, heart, colon, or spleen. Tumor size measurements showed that tumor development was significantly inhibited by treatments with (131)I-antiEGFR-BSA-PCL and (131)I-BSA-PCL. The volume of tumor increased, and treatment rate with (131)I-antiEGFR-BSA-PCL was 124% ± 7%, lower than that with (131)I-BSA-PCL (127% ± 9%), (131)I (143% ± 7%), and normal saline (146% ± 10%). The percentage losses in original body weights were 39% ± 3%, 41% ± 4%, 49% ± 5%, and 55% ± 13%, respectively. The best survival and cure rates were obtained in the group treated with (131)I-antiEGFR-BSA-PCL. The animals injected with (131)I-antiEGFR-BSA-PCL and (131)I-BSA-PCL showed more uniform focused liposome distribution within the tumor area.This study demonstrated the potential beneficial application of (131)I-antiEGFR-BSA-PCL for treating colorectal cancer. (131)I-antiEGFR-BSA-PCL suppressed the development of xenografted colorectal cancer in nude mice, thereby providing a novel candidate for receptor-mediated targeted radiotherapy." @default.
• W2316987218 created "2016-06-24" @default.
• W2316987218 creator A5016340724 @default.
• W2316987218 creator A5023506867 @default.
• W2316987218 creator A5026320292 @default.
• W2316987218 creator A5031810848 @default.
• W2316987218 creator A5042143812 @default.
• W2316987218 creator A5045203924 @default.
• W2316987218 creator A5067727675 @default.
• W2316987218 creator A5080283192 @default.
• W2316987218 date "2016-01-01" @default.
• W2316987218 modified "2023-09-26" @default.
• W2316987218 title "Evaluation of therapeutic effectiveness of¹³¹I-antiEGFR-BSA-PCL in a mouse model of colorectal cancer" @default.
• W2316987218 cites W1849788055 @default.
• W2316987218 cites W1911889560 @default.
• W2316987218 cites W1965855929 @default.
• W2316987218 cites W1968007097 @default.
• W2316987218 cites W1975235212 @default.
• W2316987218 cites W2002959795 @default.
• W2316987218 cites W2003984058 @default.
• W2316987218 cites W2013470095 @default.
• W2316987218 cites W2014289605 @default.
• W2316987218 cites W2020830322 @default.
• W2316987218 cites W2023929608 @default.
• W2316987218 cites W2025984190 @default.
• W2316987218 cites W2034307767 @default.
• W2316987218 cites W2038611143 @default.
• W2316987218 cites W2046147369 @default.
• W2316987218 cites W2057458801 @default.
• W2316987218 cites W2074544404 @default.
• W2316987218 cites W2077846439 @default.
• W2316987218 cites W2082271875 @default.
• W2316987218 cites W2086439640 @default.
• W2316987218 cites W2093951804 @default.
• W2316987218 cites W2101123723 @default.
• W2316987218 cites W2115052854 @default.
• W2316987218 cites W2131059538 @default.
• W2316987218 cites W2133453529 @default.
• W2316987218 cites W2135091780 @default.
• W2316987218 cites W2149402868 @default.
• W2316987218 cites W2153484092 @default.
• W2316987218 cites W2155977076 @default.
• W2316987218 cites W2156969927 @default.
• W2316987218 cites W2157824687 @default.
• W2316987218 cites W2163350682 @default.
• W2316987218 cites W2170957156 @default.
• W2316987218 cites W2315619948 @default.
• W2316987218 doi "https://doi.org/10.3748/wjg.v22.i14.3758" @default.
• W2316987218 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4814738" @default.
• W2316987218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27076760" @default.
• W2316987218 hasPublicationYear "2016" @default.
• W2316987218 type Work @default.
• W2316987218 sameAs 2316987218 @default.
• W2316987218 citedByCount "12" @default.
• W2316987218 countsByYear W23169872182016 @default.
• W2316987218 countsByYear W23169872182017 @default.
• W2316987218 countsByYear W23169872182018 @default.
• W2316987218 countsByYear W23169872182019 @default.
• W2316987218 countsByYear W23169872182020 @default.
• W2316987218 countsByYear W23169872182021 @default.
• W2316987218 countsByYear W23169872182022 @default.
• W2316987218 crossrefType "journal-article" @default.
• W2316987218 hasAuthorship W2316987218A5016340724 @default.
• W2316987218 hasAuthorship W2316987218A5023506867 @default.
• W2316987218 hasAuthorship W2316987218A5026320292 @default.
• W2316987218 hasAuthorship W2316987218A5031810848 @default.
• W2316987218 hasAuthorship W2316987218A5042143812 @default.
• W2316987218 hasAuthorship W2316987218A5045203924 @default.
• W2316987218 hasAuthorship W2316987218A5067727675 @default.
• W2316987218 hasAuthorship W2316987218A5080283192 @default.
• W2316987218 hasBestOaLocation W23169872181 @default.
• W2316987218 hasConcept C110121322 @default.
• W2316987218 hasConcept C121608353 @default.
• W2316987218 hasConcept C126322002 @default.
• W2316987218 hasConcept C134306372 @default.
• W2316987218 hasConcept C142724271 @default.
• W2316987218 hasConcept C185592680 @default.
• W2316987218 hasConcept C2779998722 @default.
• W2316987218 hasConcept C2780931953 @default.
• W2316987218 hasConcept C33923547 @default.
• W2316987218 hasConcept C502942594 @default.
• W2316987218 hasConcept C526805850 @default.
• W2316987218 hasConcept C71924100 @default.
• W2316987218 hasConceptScore W2316987218C110121322 @default.
• W2316987218 hasConceptScore W2316987218C121608353 @default.
• W2316987218 hasConceptScore W2316987218C126322002 @default.
• W2316987218 hasConceptScore W2316987218C134306372 @default.
• W2316987218 hasConceptScore W2316987218C142724271 @default.
• W2316987218 hasConceptScore W2316987218C185592680 @default.
• W2316987218 hasConceptScore W2316987218C2779998722 @default.
• W2316987218 hasConceptScore W2316987218C2780931953 @default.
• W2316987218 hasConceptScore W2316987218C33923547 @default.
• W2316987218 hasConceptScore W2316987218C502942594 @default.
• W2316987218 hasConceptScore W2316987218C526805850 @default.
• W2316987218 hasConceptScore W2316987218C71924100 @default.
• W2316987218 hasIssue "14" @default.
• W2316987218 hasLocation W23169872181 @default.
• W2316987218 hasLocation W23169872182 @default.

• next